Interleukin-1 Receptors (Interleukin 1 Receptor)

Cell surface receptors that are specific for INTERLEUKIN-1. Included under this heading are signaling receptors, non-signaling receptors and accessory proteins required for receptor signaling. Signaling from interleukin-1 receptors occurs via interaction with SIGNAL TRANSDUCING ADAPTOR PROTEINS such as MYELOID DIFFERENTIATION FACTOR 88.

Also Known As:

Interleukin 1 Receptor; Receptors, Interleukin 1; Receptors, Interleukin-1; IL1 Receptors; IL 1 Receptor; IL 1 Receptors; Interleukin 1 Receptors; Receptor, IL-1; Receptor, IL1; Receptor, Interleukin 1; Receptors, IL 1; Receptors, IL1; IL-1 Receptor; IL-1 Receptors; IL1 Receptor; Interleukin-1 Receptor; Receptor, Interleukin-1; Receptors, IL-1

Networked: 3600 relevant articles (179 outcomes, 479 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dinarello, Charles A: 32 articles (01/2022 - 02/2002)
2.	Iwakura, Yoichiro: 29 articles (01/2021 - 08/2002)
3.	Rothwell, Nancy J: 17 articles (01/2018 - 03/2003)
4.	Abbate, Antonio: 15 articles (01/2022 - 02/2002)
5.	Gabay, Cem: 15 articles (10/2021 - 03/2002)
6.	Mantovani, Alberto: 14 articles (10/2022 - 03/2003)
7.	Garlanda, Cecilia: 13 articles (10/2022 - 03/2004)
8.	Ueland, Thor: 13 articles (10/2018 - 08/2009)
9.	Cantarini, Luca: 12 articles (01/2021 - 01/2013)
10.	Ryffel, Bernhard: 12 articles (01/2018 - 07/2007)

Related Diseases

1.	Inflammation (Inflammations) 01/01/2019 - "Notably, rats treated with IL-1 receptor antagonist (IL-1Ra) show reduced inflammation and improved cardiac remodeling and function following Cat.G delivery. " 07/01/2003 - "Inhibitors of iNOS or IL-1 receptor may be beneficial for controlling lacrimal gland inflammation." 01/01/2021 - "Herein, we report a pilot series of LVAD patients treated with interleukin-1 receptor antagonism as a biologic adjuvant that safely and effectively treated inflammation so as to create a milieu whereby the heart could functionally improve. " 07/01/1994 - "Administration of exogenous interleukin-1 receptor antagonist (IL-1ra) is effective in reducing the severity of disease in animal models of acute inflammation. " 08/06/2010 - "Deficiency of Psgl-1 is associated with reduced IL-1 receptor-mediated adhesive properties of the endothelium and is protective against visceral fat inflammation in obese mice."
2.	Rheumatoid Arthritis 07/21/2005 - "Strategies designed to blocking IL-1beta by passive administration of inhibitors (mAbs, IL-1 receptor antagonist) have previously demonstrated efficacy in rheumatoid arthritis (RA). " 04/01/2001 - "The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis." 07/01/1996 - "To preliminarily evaluate the safety and efficacy of different dose levels and dosing frequencies of recombinant human interleukin-1 receptor antagonist (rHuIL-1Ra) in the treatment of patients with rheumatoid arthritis (RA). " 02/01/2015 - "One such therapeutic molecule IL-1 receptor antagonist (IL-1ra), used in the treatment of rheumatoid arthritis, has displayed only modest efficacy in human clinical trials owing to its short biological half-life. " 11/01/2006 - "The purpose of this study was to determine the relationship between polymorphisms of IL-1 receptor antagonist (IL-1RN), IL-1B promoter and IL-1B exon 5 genes and susceptibility to rheumatoid arthritis (RA) in Turkish population. "
3.	Arthritis (Polyarthritis) 03/01/1999 - "Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data." 06/03/2016 - "Toll/Interleukin-1 Receptor Domain Derived from TcpC (TIR-TcpC) Ameliorates Experimental Autoimmune Arthritis by Down-modulating Th17 Cell Response." 01/01/2012 - "The present study reveals two distinct subpopulations of arthritic mice with spontaneous arthritis due to deficiency for interleukin-1 receptor antagonist, suggesting that genes with function relevant to myeloid cell and/or apoptotic activities are most likely the key candidate genes for the QTL." 06/01/1995 - "Moreover, the analysis of sera taken at the end of the study period showed that the neutralization of arthritis by IL-1 receptor antibody treatment was accompanied by significantly lower levels of circulating human TNF compared to the control groups and to untreated transgenic mice prior to disease onset. " 06/01/1995 - "In the present study, we have investigated the involvement of the type I IL-1 receptor in the development and progression of chronic arthritis in a previously described TNF-transgenic mouse model of this disease. "
4.	Sepsis (Septicemia) 07/01/1997 - "To determine the therapeutic efficacy and safety of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in the treatment of patients with severe sepsis. " 08/01/1992 - "The current experiments were designed to evaluate the therapeutic efficacy of a human recombinant interleukin-1 receptor antagonist (IL-1ra) against polymicrobial gram-negative septicemia in rats. " 01/01/2018 - "We report a heterogeneous effect of recombinant human interleukin-1 receptor antagonist on 28-day sepsis mortality that is potentially predictable by plasma interleukin-1 receptor antagonist in one trial. " 02/01/2016 - "Reanalysis of deidentified data from the phase III randomized interleukin-1 receptor antagonist trial in severe sepsis. " 01/01/2015 - "Many studies have focused on the relationship between interleukin 1 receptor antagonist (IL1RN) gene 86-bp VNTR polymorphism and sepsis, but the results remain inconsistent. "
5.	Experimental Arthritis 04/01/2008 - "Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis." 09/01/2003 - "Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist." 05/01/1997 - "To determine the efficacy of local human interleukin-1 receptor antagonist (HuIL-1Ra) gene therapy in murine collagen-induced arthritis (CIA). " 01/01/2018 - "Mesenchymal stem cells ameliorate experimental arthritis via expression of interleukin-1 receptor antagonist." 11/01/2011 - "Inhibition of adjuvant arthritis in rats by electroporation with interleukin-1 receptor antagonist."

Related Drugs and Biologics

1.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
2.	Interleukin-1 (Interleukin 1)
3.	Cytokines
4.	Interleukin-6 (Interleukin 6)
5.	Proteins (Proteins, Gene)
6.	Interleukin-10 (Interleukin 10)
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
8.	Interleukin-1beta (Interleukin 1 beta)
9.	Interleukins
10.	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Transplantation
4.	Biological Therapy
5.	Glycemic Control